<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934007</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A02544-49</org_study_id>
    <nct_id>NCT04934007</nct_id>
  </id_info>
  <brief_title>Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder</brief_title>
  <acronym>ORBITOC3</acronym>
  <official_title>A Randomized Control Trial of Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Henri Laborit</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Henri Laborit</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a&#xD;
      relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in&#xD;
      Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale score</measure>
    <time_frame>baseline and 25 days</time_frame>
    <description>Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale</measure>
    <time_frame>baseline and 70 days</time_frame>
    <description>Significant clinical change of the YBOCS score (≥25% decrease), from baseline to day 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general assessement functioning (GAF)</measure>
    <time_frame>baseline and 25 days</time_frame>
    <description>Change of the general assessement functioning (GAF) at day 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>general assessement functioning (GAF)</measure>
    <time_frame>baseline and 70 days</time_frame>
    <description>Change of the general assessement functioning (GAF) at day 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>baseline and 25 days</time_frame>
    <description>Clinical Global Impressions (CGI) change at day 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>baseline and 70 days</time_frame>
    <description>Clinical Global Impressions (CGI) change at day 70</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events linked to the rTMS treatment</measure>
    <time_frame>70 days</time_frame>
    <description>Number and types of adverse events linked to the rTMS treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active rTMS stimulation , 2 session per day during 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham rTMS stimulation , 2 session per day during 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rTMS Treatment</intervention_name>
    <description>1 Hz rTMS</description>
    <arm_group_label>Active stimulation</arm_group_label>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: Participants will be both males and females, 18-65 years of age included.&#xD;
&#xD;
          -  diagnosis of OCD&#xD;
&#xD;
          -  all the patients must have failed to respond to at least two different pharmacological&#xD;
             treatment used for at least 6 weeks&#xD;
&#xD;
          -  Affiliation to a social security system (recipient or assignee),&#xD;
&#xD;
          -  Signed written inform consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The exclusion criteria are a diagnosis of another psychiatric disorder (except for&#xD;
             anxious disorders), a diagnosis of a significant active medical illness, pregnancy or&#xD;
             other neurological illness&#xD;
&#xD;
          -  In accordance with the safety criteria for rTMS, patients with a history of seizure or&#xD;
             bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips&#xD;
             placed inside the skull will also be excluded&#xD;
&#xD;
          -  The patients won't be allowed to change their medication during the trial. The&#xD;
             treatment must be stable at least 3 week before day 0.&#xD;
&#xD;
          -  Female subject who is pregnant, or of child-bearing age, sexually active and not using&#xD;
             reliable contraception or who is nursing,&#xD;
&#xD;
          -  Patient under curators&#xD;
&#xD;
          -  Patient hospitalized under duress&#xD;
&#xD;
          -  Patient unable to give his or hers informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghina Harika-Germaneau</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Henri Laborit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghina Harika-Germaneau, MD, PhD</last_name>
    <phone>+33 5 16 52 61 18</phone>
    <email>ghina.harika.germaneau@ch-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nematollah Jaafari, PR</last_name>
    <phone>+33 5 16 52 61 18</phone>
    <email>nemat.jaafari@ch-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sorbonne University, Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Millet, PR</last_name>
      <email>b.millet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Laborit</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghina Harika-Germaneau, MD, PhD</last_name>
      <phone>+33 5 16 52 61 18</phone>
      <email>ghina.harika-germaneau@ch-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rTMS</keyword>
  <keyword>D-B80 A/P</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

